1. Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients
- Author
-
Siggelkow Wulf, Boehm Daniel, Gebhard Susanne, Battista Marco, Sicking Isabel, Lebrecht Antje, Solbach Christine, Hellwig Birte, Rahnenführer Jörg, Koelbl Heinz, Gehrmann Mathias, Marchan Rosemarie, Cadenas Cristina, Hengstler Jan G, and Schmidt Marcus
- Subjects
Aurora kinase ,Node-negative breast cancer ,Breast cancer ,Prognosis ,Aurora kinase inhibitors ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Inhibitors targeting the cell cycle-regulated aurora kinase A (AURKA) are currently being developed. Here, we examine the prognostic impact of AURKA in node-negative breast cancer patients without adjuvant systemic therapy (n = 766). Methods AURKA was analyzed using microarray-based gene-expression data from three independent cohorts of node-negative breast cancer patients. In multivariate Cox analyses, the prognostic impact of age, histological grade, tumor size, estrogen receptor (ER), and HER2 were considered. Results Patients with higher AURKA expression had a shorter metastasis-free survival (MFS) in the Mainz (HR 1.93; 95% CI 1.34 – 2.78; P < 0.001), Rotterdam (HR 1.95; 95% CI 1.45– 2.63; P Conclusions AURKA is associated with worse prognosis in estrogen receptor positive breast carcinomas. Patients with the highest AURKA expression (>75% percentile) have a particularly bad prognosis and may profit from therapy with AURKA inhibitors.
- Published
- 2012
- Full Text
- View/download PDF